Innovative therapeutics

Investors

BioMarin Announces 20 Poster Presentations at Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018
Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)
Sep 5, 2018

SAN RAFAEL, Calif., Sept. 5, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium 2018, which will be held on September 4-7 in Athens, Greece. 

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Listing of Posters and Presentations at Society for the Study of Inborn Errors of Metabolism 2018 Symposium

Poster Presentations

CLN2 Disease

Title

Authors

Monitoring neuropsychological function in CLN2 disease

 

Poster: #345

Nickel M, Augustine E, Adams H, Baron I, Bjoraker K, Cohen-Pfeffer J, Delaney K, Elmerskog B, Newsom-Davis I, Rust S, Shapiro E, Tøssebro A, Schulz A

Experiences of CLN2 disease diagnosis in the UK

 

Poster: #357

Burke D, Church H, Jackson M, Powers V, Tylee K

Intracerebroventricular cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study

 

Poster: #367

Schulz A, de los Reyes E, Specchio N, Gissen P, Cahan H, Slasor P, Ajayi T, Jacoby D


Phenylketonuria (PKU)

Title

Authors

Burden of illness in adult patients with phenylketonuria and associated comorbidities – a retrospective database study in Germany

 

Poster: #095

Rutsch F, Muntau AC, Alvarez I, Lane P, Altevers J, Kohlscheen KM, Jacob C, Jain M, Schroeder C,

Jha A, Treftz F

Efficacy & safety of sapropterin in PKU patients <4 yrs: 3-year extension of SPARK open-label, randomized phase 3b trial

 

Poster: #097

Rutsch F, Burlina A, Eyskens F, Freisinger P,

De Laet C, Leuzzi V, Sivri HS, Vijay S, Bal MO, Gramer G, Pazdírková R, Cleary M, Lotz-Havla AS, Mould DR, Lane P, Alvarez I, Muntau A

Prevalence of comorbidities among phenylketonuria patients – a retrospective study of US health insurance claims data

 

Poster: #098

Burton B, Cederbaum S, Jurecki E, Lilienstein J, Alvarez I, Cohen-Pfeffer J, Irwin D, Levy H, Rohr

The burden of illness in adults with phenylketonuria (PKU): interim analysis of a cross-sectional study

 

Poster: #099

Burton B, Longo N, Stuy M, Vockley J, van Backle J, Lane P, Alvarez I, Lilienstein J, Jurecki E

International best practice recommendations for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria

 

Poster: #117

Bhattacharya K, Adams D, Belanger-Quintana A, Bushueva T, Cerone R, Chien N, Chiesa A, Coskun T, De la Heras Montero J, Feillet F, Katz R, Lagler F, Muntau A, Piazzon F, Rohr F, Spronsen F, Vargas P, Wilcox G

Phase 3 PRISM clinical trials evaluating efficacy and safety of pegvaliase for treatment of adults with phenylketonuria

 

Poster: #122

Thomas J, Levy H, Amato S, Vockley G, Zori R, Dimmock C, Harding C, Bilder D, Weng HH, Olbertz J, Merilainen M, Rosen O, Gupta S, Gu K, Larimore K, Northrup H

Long-term safety of induction, titration, and maintenance dosing of pegvaliase treatment in adults with phenylketonuria

 

Poster: #123

Burton B, Harding C, Thomas J, Longo N, Posner J, Dimmock D, Zori R, Weng H, Olbertz J, Gershman E, Rosen O, Gupta S, Jones S, Gu K, Vockley J

Characterization of hypophenylalaninemia in pegvaliase treated adults with PKU

 

Poster: #124

Harding C, Thomas J, Burton B, Zori R, Dimmock D, Vockley J, Weng HH, Olbertz J, Gershman A,

Rosen O, Jones S, Li M, Longo N

An interim analysis of the KAMPER and PKUDOS registries: efficacy and safety of sapropterin before and during pregnancy

 

Poster: #125

Feillet F, Ficicioglu C, Lagler FB, Longo N, Alm J, Muntau AC, Burlina A, Belanger-Quintana A, Trefz FK, Kittus R, Jurecki E, Alvarez I, Lilienstein J, Burton B

A meta-analysis of growth outcomes in phenylketonuria patients treated with phenylalanine-restricted diet + sapropterin

 

Poster: #126

Muntau A, Feillet F, Burton B, McDonald A, Wessel A, Alvarez I, Lilienstein J, Lane P, Jurecki E, Longo N


Mucopolysaccharidosis (MPS)

Title

Authors

Natural history data for young subjects with Sanfilippo syndrome type B (MPS IIIB)

 

Poster: #315

Harmatz P, Cleary M, de Castro Lopez MJ, Lee J, Lin S, Okur I, Ezgu F, Muschol N, Peters H, Solano Villarreal MS, Shaywitz AJ, Cahan H, Grover A, Maricich SM, Melton A, Smith L, Couce ML

ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)

 

Poster: #316

Lin S, Cleary M, Couce ML, de Castro Lopez MJ, Harmatz P, Lee J, Okur I, Ezgu F, Peters H, Villarreal MS, Shaywitz AJ, Cahan H, Grover A, Maricich SM, Melton A, Smith L, Muschol N

Critical care situations in patients with mucopolysaccharidosis (MPS)

 

Poster: #321

Stepien K, Geavorkian A, Hendriksz C, Lobzhanidze T, Perez-Lopez J, del Toro M, Vashakmadze N, Lampe C

Transition from paediatric to adult care in patients with mucopolysaccharidosis (MPS)

 

Poster: #324

Lampe C, McNelly B, Geavorkian A, Hendriksz C, Lobzhanidze T, Perez-Lopez J, Vashakmadze N,

del Toro M

Mucopolysaccharidosis VI enzyme replacement therapy outcomes across the disease spectrum:  findings from the MPS VI clinical surveillance program

 

Poster: #362

Harmatz P, Lampe C, Teles EL, Parini R, Sharma R, Sivam D, Johnson J, Hawley S, Sisic Z

Enzyme replacement therapy in patients with mucopolysaccharidosis VI: updated findings from the MPS VI clinical surveillance program

 

Poster: #363

Harmatz P, Lampe C, Leão-Teles E, Parini R, Sharma R, Sivam D, Johnson J, Sisic Z

Mucopolysaccharidosis VI enzyme replacement therapy initiated in adulthood: findings from the MPS VI clinical surveillance program

 

Poster: #364

Lampe C, Harmatz, Leão-Teles E, Parini R, Sharma R, Sivam D, Johnson J, Hawley S, Sisic Z

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. 

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.

Contact:

Investors: 

Media:

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558 

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information